fg-4592 profile

roxadustat: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

roxadustat : An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Glycine	genus	A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]	Fabaceae	The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

ID Source	ID
PubMed CID	11256664
CHEMBL ID	2338329
CHEBI ID	132774
SCHEMBL ID	523705
MeSH ID	M0589156

Synonym
fg-4592 ,
roxadustat
CHEBI:132774
808118-40-3
fg4592
n-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine
roxadustatum
fg 4592
n-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine
bdbm50431015
glycine, n-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-
BCP9000684
HY-13426
CS-1094
BCPP000230
fg-4592,asp1517
roxadustat (fg-4592)
NCGC00346527-01
(((4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)amino)acetic acid
roxadustat [usan:inn]
x3o30d9ymx ,
asp 1517
unii-x3o30d9ymx
S1007
roxadustat [who-dd]
roxadustat [jan]
glycine, n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)-
roxadustat [inn]
roxadustat [usan]
n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine
asp1517
asp-1517
CHEMBL2338329 ,
MLS006010023
smr004701207
SCHEMBL523705
DTXSID60230644
roxadustat (jan/usan/inn)
evrenzo (tn)
D10593
gtpl8454
evrenzo
2-[[4-hydroxy-1-methyl-7-(phenoxy)isoquinoline-3-carbonyl]amino]acetic acid
(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine
AC-31003
2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
fg-4592[roxadustat]
AKOS026674331
J-522733
EX-A390
2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid
HMS3654M03
mfcd20040519
NCGC00346527-07
YOZBGTLTNGAVFU-UHFFFAOYSA-N
SW219900-1
roxadustat(fg-4592)
DB04847
Q27088611
AS-17052
BCP02523
AMY16514
8ho ,
2-[(1-methyl-4-oxidanyl-7-phenoxy-isoquinolin-3-yl)carbonylamino]ethanoic acid
SB16615
CCG-268052
n-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-glycine, roxadustat

Excerpt	Reference
" Roxadustat was considered safe and well tolerated when administered alone or in combination with multiple daily oral doses of 40 mg omeprazole in healthy subjects."	( Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects. Barroso-Fernandez, B; den Adel, M; El Galta, R; Golor, G; Groenendaal-van de Meent, D; Schaddelee, M; van Dijk, J, 2018)
" As for safety, the incidence of adverse events (AEs) in the roxadustat group was insignificantly different from that of the placebo group [risk ratio (RR) 0."	( The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis. Fu, X; Huang, Y; Liu, WJ; Liu, YN; Wang, Y; Wei, R; Yang, H; Zheng, Q, 2021)
" No difference was found between roxadustat and control group in terms of oral iron supplementation, adverse events (AEs), serious adverse events (SAEs), infection, myocardial infraction, stroke, heart failure and death."	( The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review. Duan, K; Jiao, N; Li, J; Liu, G; Liu, Y; Qie, S, 2021)
" Pooled safety endpoints included time to major adverse cardiovascular event (MACE; myocardial infarction, stroke, and all-cause mortality [ACM]) and MACE+ (MACE plus congestive heart failure or unstable angina requiring hospitalization), ACM, and treatment-emergent adverse events (TEAEs)."	( Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Barratt, J; Csiky, B; Esposito, C; Reusch, M; Schömig, M; Sulowicz, W; Young, J, 2021)
" The patients were followed up every 2 weeks, and the changes in their hemoglobin index and any adverse reactions were recorded during 10 weeks of treatment."	( Efficacy and safety of roxadustat in the treatment of renal allograft anemia patients: a case series. Li, J; Lv, J; Ma, K; Peng, W; Qi, H; Rao, Y; Wang, L, 2021)
" Only one person showed symptoms of fatigue, and there were no other obvious adverse reactions reported."	( Efficacy and safety of roxadustat in the treatment of renal allograft anemia patients: a case series. Li, J; Lv, J; Ma, K; Peng, W; Qi, H; Rao, Y; Wang, L, 2021)
"We concluded that ROX increased Hb level and improved iron utilization parameters in NDD-CKD patients, but ROX was associated with higher serious adverse effects, especially DVT and HTN."	( The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials. Abbas, KS; Abdelazeem, B; El-Shahat, NA; Eltobgy, M; Kunadi, A; Malik, B; Savarapu, P; Shehata, J, 2022)
" The Morisky Medication Adherence Scale-8 (MMAS-8) was used to score medication compliance during rhEPO treatment and roxadustat treatment, and adverse reactions occurred during treatment were collected."	( Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study. Bao, L; Bian, X; Huang, J; Luo, C; Ren, L; Zhang, A, 2022)
" There were no serious adverse events associated with roxadustat were observed."	( Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study. Bao, L; Bian, X; Huang, J; Luo, C; Ren, L; Zhang, A, 2022)
" In terms of safety, roxadustat treatment did not increase risk of total adverse events either in dialysis-dependent or not dialysis-dependent patients."	( Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients. Lei, J; Li, H; Wang, S, 2022)
" There was no significant difference in total adverse events compared with the control group."	( Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients. Lei, J; Li, H; Wang, S, 2022)

Excerpt	Reference
" Pharmacodynamic evaluation was performed in a subset of subjects."	( Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Besarab, A; Hemmerich, S; Hertel, J; Klaus, SJ; Lee, T; Leong, R; Neff, TB; Provenzano, R; Yu, KH; Zabaneh, R, 2015)
" This clinical trial was designed to evaluate the effect of roxadustat on warfarin pharmacokinetic and pharmacodynamic parameters."	( The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study. den Adel, M; Golor, G; Groenendaal-van de Meent, D; Kerbusch, V; Krebs-Brown, A; Rijnders, S; Schaddelee, M, 2016)
" Pharmacokinetic and pharmacodynamic parameters were estimated via noncompartmental methods."	( The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study. den Adel, M; Golor, G; Groenendaal-van de Meent, D; Kerbusch, V; Krebs-Brown, A; Rijnders, S; Schaddelee, M, 2016)
"The geometric mean ratios and 90% CIs for Cmax and AUC∞ of total and unbound S- and R-warfarin (with and without roxadustat) were within the standard bioequivalence interval of 80."	( The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study. den Adel, M; Golor, G; Groenendaal-van de Meent, D; Kerbusch, V; Krebs-Brown, A; Rijnders, S; Schaddelee, M, 2016)
"Based on the lack of clinically significant pharmacokinetic interactions and the limited influence on warfarin pharmacodynamic parameters, no dose adjustment of warfarin should be required when coadministered with roxadustat."	( The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study. den Adel, M; Golor, G; Groenendaal-van de Meent, D; Kerbusch, V; Krebs-Brown, A; Rijnders, S; Schaddelee, M, 2016)
" Mean terminal half-life (t ½) appeared to be longer (17."	( Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. Adel, MD; Alexiev, A; Groenendaal-van de Meent, D; Krebs-Brown, A; Mateva, L; Noukens, J; Rijnders, S; Schaddelee, M, 2016)
" Maximum plasma concentration and area under the plasma concentration-time curve for patients receiving roxadustat were slightly more than dose proportional and elimination half-life ranged from 14."	( Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. Chou, J; Hemmerich, S; Neff, TB; Provenzano, R; Tumlin, J; Yu, KP; Zabaneh, R, 2020)
" A population pharmacokinetic analysis was undertaken to evaluate the effect of intrinsic and extrinsic factors on roxadustat pharmacokinetics."	( Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. Åstrand, M; Bradley, C; Chou, J; Hamrén, B; Huang, J; Kerbusch-Herben, V; Någård, M; Rekić, D; Tannenbaum, S, 2021)
"A population pharmacokinetic model was developed for the pharmacokinetics of roxadustat in the target population."	( Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. Åstrand, M; Bradley, C; Chou, J; Hamrén, B; Huang, J; Kerbusch-Herben, V; Någård, M; Rekić, D; Tannenbaum, S, 2021)
" This study in healthy individuals investigated the effect of 2 PBs, sevelamer carbonate and calcium acetate, on the pharmacokinetic properties of a single oral dose of roxadustat administered concomitantly or with a time lag."	( Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals. Barroso-Fernandez, B; den Adel, M; Golor, G; Groenendaal-van de Meent, D; Kerbusch, V; Schaddelee, M; van Dijk, J, 2021)
"Our objective was to develop a population pharmacokinetic (PK) model to describe roxadustat plasma concentrations in Japanese dialysis-dependent chronic kidney disease (DD-CKD) patients with renal anaemia and to identify the covariate factors that affect exposure of roxadustat."	( Population pharmacokinetics of roxadustat in Japanese dialysis-dependent chronic kidney disease patients with anaemia. Groenendaal-van de Meent, D; Komatsu, K; Shibata, T; Shiga, T; Takada, A, 2022)
" This proposed method was fully validated and applied to the pharmacokinetic (PK) and pharmacodynamic (PD) study of roxadustat among healthy subjects in China."	( Liquid chromatography-tandem mass spectrometry methods for quantification of roxadustat (FG-4592) in human plasma and urine and the applications in two clinical pharmacokinetic studies. Chen, X; Cui, X; Hu, P; Jiang, J; Liu, T; Zhao, Q; Zheng, X, 2022)

Excerpt	Reference
" Roxadustat (FG-4592) is an orally bioavailable hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that promotes coordinated erythropoiesis through HIF-mediated transcription."	( Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. Besarab, A; Chan, DT; Chernyavskaya, E; Franco, M; Gurevich, K; Hemmerich, S; Kumbar, LM; Leong, R; Motylev, I; Neff, TB; Poole, L; Saikali, KG; Shutov, E; Yu, KH; Zhong, M, 2016)
" These are potent, selective, orally bioavailable across several species, and active in stimulating erythropoiesis."	( Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia. Clements, MJ; Debenham, JS; DeMartino, JA; Hajdu, R; Hale, JJ; Kuethe, JT; Lingham, RB; Madsen-Duggan, C; Miller, RR; Milligan, JA; Pang, J; Reibarkh, M; Salowe, SP; Sherer, EC; Sonatore, LM; Stickens, D; Tong, X; Visco, DM; Walsh, TF; Wolff, M; Zhou, D, 2016)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)
"The roxadustat PK data in Japanese DD-CKD patients with renal anaemia were well described by a 2-compartment disposition model with first-order absorption and interindividual variability on clearance, central volume of distribution and absorption rate constant."	( Population pharmacokinetics of roxadustat in Japanese dialysis-dependent chronic kidney disease patients with anaemia. Groenendaal-van de Meent, D; Komatsu, K; Shibata, T; Shiga, T; Takada, A, 2022)
" The identified key covariates included coadministration of PBs on the roxadustat bioavailability and age on clearance of roxadustat."	( Population pharmacokinetics of roxadustat in Japanese dialysis-dependent chronic kidney disease patients with anaemia. Groenendaal-van de Meent, D; Komatsu, K; Shibata, T; Shiga, T; Takada, A, 2022)

Excerpt	Reference
"Of 116 subjects receiving treatment, 104 completed 4 weeks of dosing and 96 were evaluable for efficacy."	( Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Besarab, A; Hemmerich, S; Hertel, J; Klaus, SJ; Lee, T; Leong, R; Neff, TB; Provenzano, R; Yu, KH; Zabaneh, R, 2015)
"8 h) in subjects with moderate hepatic impairment, however intersubject variability on apparent total systemic clearance after single oral dosing (CL/F), apparent volume of distribution at equilibrium after oral administration (V z/F) and t ½ was approximately twofold higher."	( Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. Adel, MD; Alexiev, A; Groenendaal-van de Meent, D; Krebs-Brown, A; Mateva, L; Noukens, J; Rijnders, S; Schaddelee, M, 2016)
" Primary outcomes for both studies were area under the concentration-time curve from the time of dosing extrapolated to infinity and maximum concentration of drug in blood plasma."	( Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects. Furihata, K; Katashima, M; Nomura, Y; Shibata, T; Takada, A; Ueno, M; Yazawa, R, 2019)
"A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients with Anemia, NCT02952092 (ClinicalTrials."	( Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. Akizawa, T; Iwasaki, M; Majikawa, Y; Reusch, M; Yamaguchi, Y, 2020)
" Roxadustat induced transient elevations of endogenous erythropoietin that peaked between 7 and 14 hours after dosing and returned to baseline by 48 hours after dosing."	( Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. Chou, J; Hemmerich, S; Neff, TB; Provenzano, R; Tumlin, J; Yu, KP; Zabaneh, R, 2020)
" Results from this study helped inform dosing and administration guidelines aimed at reducing interactions between roxadustat and these PBs."	( Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals. Barroso-Fernandez, B; den Adel, M; Golor, G; Groenendaal-van de Meent, D; Kerbusch, V; Schaddelee, M; van Dijk, J, 2021)
" Dosage adjustments were administrated according to the fluctuation of hemoglobin level during the treatment."	( Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation. Chen, XX; Lou, JZ; Yuan, HB; Zhang, YF; Zhou, Y, 2021)
" This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness."	( Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients. Akizawa, T; Otsuka, T; Tanaka-Amino, K; Yamaguchi, Y, 2021)
" Oral roxadustat dosed thrice weekly was well tolerated."	( Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study. Bartels, P; Bradley, C; Carraway, HE; Glaspy, J; Harrup, R; Henry, DH; Leong, R; Mittelman, M; Modelska, K; Saha, G; Yu, KP; Zhou, A, 2022)

Role	Description
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor	An EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor that interferes with the action of procollagen-proline dioxygenase (EC 1.14.11.2).
EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor	An EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor that interferes with the action of hypoxia-inducible factor-proline dioxygenase (EC 1.14.11.29).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
isoquinolines	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
N-acylglycine	An N-acyl-amino acid in which amino acid specified is glycine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	5.8992	0.0013	10.1577	42.8575	AID1259252
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Prolyl 4-hydroxylase	Paramecium bursaria Chlorella virus 1	IC50 (µMol)	5.0000	5.0000	6.2667	8.5000	AID1543452
Prolyl 4-hydroxylase	Paramecium bursaria Chlorella virus 1	Ki	1.0700	1.0700	2.1750	3.2800	AID1543452
Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)	IC50 (µMol)	1.0000	1.0000	1.0000	1.0000	AID1543455
Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)	IC50 (µMol)	9.8000	3.0000	6.1000	9.8000	AID734755
Egl nine homolog 1	Homo sapiens (human)	IC50 (µMol)	0.8836	0.0070	1.8614	8.0000	AID1280627; AID1497709; AID1497712; AID1543453; AID1576662; AID1675363; AID1735098; AID1884425; AID1901053; AID1910214
Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)	IC50 (µMol)	100.0000	8.6000	8.6000	8.6000	AID1543454
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Thyroid hormone receptor alpha	Homo sapiens (human)	EC50 (µMol)	0.0327	0.0004	0.2584	3.7400	AID1910211
Thyroid hormone receptor beta	Homo sapiens (human)	EC50 (µMol)	0.0129	0.0002	0.0348	0.2400	AID1910212
Egl nine homolog 1	Homo sapiens (human)	EC50 (µMol)	6.1100	6.1100	6.1100	6.1100	AID1917455
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cartilage condensation	Thyroid hormone receptor alpha	Homo sapiens (human)
ossification	Thyroid hormone receptor alpha	Homo sapiens (human)
regulation of thyroid hormone mediated signaling pathway	Thyroid hormone receptor alpha	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Thyroid hormone receptor alpha	Homo sapiens (human)
transcription by RNA polymerase II	Thyroid hormone receptor alpha	Homo sapiens (human)
learning or memory	Thyroid hormone receptor alpha	Homo sapiens (human)
regulation of heart contraction	Thyroid hormone receptor alpha	Homo sapiens (human)
female courtship behavior	Thyroid hormone receptor alpha	Homo sapiens (human)
response to cold	Thyroid hormone receptor alpha	Homo sapiens (human)
hormone-mediated signaling pathway	Thyroid hormone receptor alpha	Homo sapiens (human)
negative regulation of RNA polymerase II transcription preinitiation complex assembly	Thyroid hormone receptor alpha	Homo sapiens (human)
erythrocyte differentiation	Thyroid hormone receptor alpha	Homo sapiens (human)
thyroid gland development	Thyroid hormone receptor alpha	Homo sapiens (human)
regulation of myeloid cell apoptotic process	Thyroid hormone receptor alpha	Homo sapiens (human)
negative regulation of DNA-templated transcription	Thyroid hormone receptor alpha	Homo sapiens (human)
positive regulation of female receptivity	Thyroid hormone receptor alpha	Homo sapiens (human)
regulation of lipid catabolic process	Thyroid hormone receptor alpha	Homo sapiens (human)
type I pneumocyte differentiation	Thyroid hormone receptor alpha	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Thyroid hormone receptor alpha	Homo sapiens (human)
negative regulation of DNA-templated transcription initiation	Thyroid hormone receptor alpha	Homo sapiens (human)
thyroid hormone mediated signaling pathway	Thyroid hormone receptor alpha	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Thyroid hormone receptor alpha	Homo sapiens (human)
cell differentiation	Thyroid hormone receptor alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Thyroid hormone receptor alpha	Homo sapiens (human)
retinoic acid receptor signaling pathway	Thyroid hormone receptor alpha	Homo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathway	Thyroid hormone receptor beta	Homo sapiens (human)
DNA-templated transcription	Thyroid hormone receptor beta	Homo sapiens (human)
sensory perception of sound	Thyroid hormone receptor beta	Homo sapiens (human)
negative regulation of female receptivity	Thyroid hormone receptor beta	Homo sapiens (human)
regulation of heart contraction	Thyroid hormone receptor beta	Homo sapiens (human)
female courtship behavior	Thyroid hormone receptor beta	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Thyroid hormone receptor beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Thyroid hormone receptor beta	Homo sapiens (human)
retinal cone cell development	Thyroid hormone receptor beta	Homo sapiens (human)
type I pneumocyte differentiation	Thyroid hormone receptor beta	Homo sapiens (human)
cellular response to thyroid hormone stimulus	Thyroid hormone receptor beta	Homo sapiens (human)
retinal cone cell apoptotic process	Thyroid hormone receptor beta	Homo sapiens (human)
retinoic acid receptor signaling pathway	Thyroid hormone receptor beta	Homo sapiens (human)
cell differentiation	Thyroid hormone receptor beta	Homo sapiens (human)
thyroid hormone mediated signaling pathway	Thyroid hormone receptor beta	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Thyroid hormone receptor beta	Homo sapiens (human)
regulation of translational termination	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
cell population proliferation	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
protein hydroxylation	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
peptidyl-proline hydroxylation	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
stress granule assembly	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
temperature homeostasis	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
DNA alkylation repair	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
regulation of lipid storage	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
snRNA processing	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
regulation of multicellular organism growth	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
RNA repair	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
regulation of respiratory system process	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
adipose tissue development	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
mRNA destabilization	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
regulation of white fat cell proliferation	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
regulation of brown fat cell differentiation	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
response to hypoxia	Egl nine homolog 1	Homo sapiens (human)
intracellular iron ion homeostasis	Egl nine homolog 1	Homo sapiens (human)
intracellular oxygen homeostasis	Egl nine homolog 1	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Egl nine homolog 1	Homo sapiens (human)
regulation of angiogenesis	Egl nine homolog 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Egl nine homolog 1	Homo sapiens (human)
negative regulation of cyclic-nucleotide phosphodiesterase activity	Egl nine homolog 1	Homo sapiens (human)
cardiac muscle tissue morphogenesis	Egl nine homolog 1	Homo sapiens (human)
heart trabecula formation	Egl nine homolog 1	Homo sapiens (human)
ventricular septum morphogenesis	Egl nine homolog 1	Homo sapiens (human)
labyrinthine layer development	Egl nine homolog 1	Homo sapiens (human)
response to nitric oxide	Egl nine homolog 1	Homo sapiens (human)
regulation of modification of postsynaptic structure	Egl nine homolog 1	Homo sapiens (human)
regulation protein catabolic process at postsynapse	Egl nine homolog 1	Homo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-proline	Egl nine homolog 1	Homo sapiens (human)
cellular response to hypoxia	Egl nine homolog 1	Homo sapiens (human)
positive regulation of myoblast differentiation	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
negative regulation of Notch signaling pathway	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
positive regulation of vasculogenesis	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Thyroid hormone receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Thyroid hormone receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity	Thyroid hormone receptor alpha	Homo sapiens (human)
nuclear receptor activity	Thyroid hormone receptor alpha	Homo sapiens (human)
protein binding	Thyroid hormone receptor alpha	Homo sapiens (human)
zinc ion binding	Thyroid hormone receptor alpha	Homo sapiens (human)
TBP-class protein binding	Thyroid hormone receptor alpha	Homo sapiens (human)
protein domain specific binding	Thyroid hormone receptor alpha	Homo sapiens (human)
chromatin DNA binding	Thyroid hormone receptor alpha	Homo sapiens (human)
thyroid hormone binding	Thyroid hormone receptor alpha	Homo sapiens (human)
general transcription initiation factor binding	Thyroid hormone receptor alpha	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Thyroid hormone receptor alpha	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Thyroid hormone receptor beta	Homo sapiens (human)
transcription coactivator binding	Thyroid hormone receptor beta	Homo sapiens (human)
DNA binding	Thyroid hormone receptor beta	Homo sapiens (human)
DNA-binding transcription factor activity	Thyroid hormone receptor beta	Homo sapiens (human)
nuclear receptor activity	Thyroid hormone receptor beta	Homo sapiens (human)
protein binding	Thyroid hormone receptor beta	Homo sapiens (human)
zinc ion binding	Thyroid hormone receptor beta	Homo sapiens (human)
enzyme binding	Thyroid hormone receptor beta	Homo sapiens (human)
chromatin DNA binding	Thyroid hormone receptor beta	Homo sapiens (human)
thyroid hormone binding	Thyroid hormone receptor beta	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Thyroid hormone receptor beta	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Thyroid hormone receptor beta	Homo sapiens (human)
iron ion binding	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
protein binding	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
L-ascorbic acid binding	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
peptidyl-proline dioxygenase activity	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
peptidyl-proline 3-dioxygenase activity	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
ferrous iron binding	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
transferase activity	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
oxidative RNA demethylase activity	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
broad specificity oxidative DNA demethylase activity	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
mRNA N6-methyladenosine dioxygenase activity	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
tRNA demethylase activity	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
protein binding	Egl nine homolog 1	Homo sapiens (human)
ferrous iron binding	Egl nine homolog 1	Homo sapiens (human)
2-oxoglutarate-dependent dioxygenase activity	Egl nine homolog 1	Homo sapiens (human)
enzyme binding	Egl nine homolog 1	Homo sapiens (human)
L-ascorbic acid binding	Egl nine homolog 1	Homo sapiens (human)
peptidyl-proline dioxygenase activity	Egl nine homolog 1	Homo sapiens (human)
hypoxia-inducible factor-proline dioxygenase activity	Egl nine homolog 1	Homo sapiens (human)
peptidyl-proline 4-dioxygenase activity	Egl nine homolog 1	Homo sapiens (human)
transcription corepressor activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
Notch binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
protein binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
ferrous iron binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
zinc ion binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
oxygen sensor activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
carboxylic acid binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
peptidyl-histidine dioxygenase activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
[protein]-asparagine 3-dioxygenase activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
protein homodimerization activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
NF-kappaB binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
peptidyl-aspartic acid 3-dioxygenase activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
ankyrin repeat binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Thyroid hormone receptor alpha	Homo sapiens (human)
nucleoplasm	Thyroid hormone receptor alpha	Homo sapiens (human)
cytosol	Thyroid hormone receptor alpha	Homo sapiens (human)
chromatin	Thyroid hormone receptor alpha	Homo sapiens (human)
nucleus	Thyroid hormone receptor alpha	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Thyroid hormone receptor alpha	Homo sapiens (human)
nucleoplasm	Thyroid hormone receptor beta	Homo sapiens (human)
nuclear body	Thyroid hormone receptor beta	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Thyroid hormone receptor beta	Homo sapiens (human)
chromatin	Thyroid hormone receptor beta	Homo sapiens (human)
nucleus	Thyroid hormone receptor beta	Homo sapiens (human)
nucleoplasm	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
cytosol	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
cytoplasmic stress granule	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
cytoplasm	Prolyl 3-hydroxylase OGFOD1	Homo sapiens (human)
nucleus	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
nucleoplasm	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
cytoplasm	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
cytosol	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
plasma membrane	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
nuclear speck	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-ketoglutarate-dependent dioxygenase FTO	Homo sapiens (human)
cytoplasm	Egl nine homolog 1	Homo sapiens (human)
cytosol	Egl nine homolog 1	Homo sapiens (human)
postsynaptic density	Egl nine homolog 1	Homo sapiens (human)
intracellular membrane-bounded organelle	Egl nine homolog 1	Homo sapiens (human)
glutamatergic synapse	Egl nine homolog 1	Homo sapiens (human)
nucleus	Egl nine homolog 1	Homo sapiens (human)
cytoplasm	Egl nine homolog 1	Homo sapiens (human)
nucleus	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
nucleoplasm	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
cytoplasm	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
cytosol	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
perinuclear region of cytoplasm	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
cytoplasm	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (123)

Assay ID	Title	Year	Journal	Article
AID1347157	Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1675344	In vivo inhibition of PHD2 in po dosed C57BL/6 mouse assessed as upregulation of EPO plasma level administered 4 times for 3 days by ELISA
AID1497731	Intrinsic aqueous solubility of the compound at pH 7.4 by potentiometric titration method	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497726	Inhibition of HIF-PHD2 in human Hep3B cells assessed as HIF-1alpha protein stabilization at 50 to 250 uM after 10 hrs by Western blot method	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1910214	Inhibition of PHD2 (unknown origin) incubated for 15 mins by competitive fluorescence polarization assay	2022	Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10	Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID1495354	Terminal half life in patient with hepatic impairment at 100 mg, po	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
AID1067647	Reduction in total cholesterol level in chronic kidney disease patient administered for 16 to 24 weeks relative to control	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.
AID1675363	Inhibition of FITC-HIF1alpha (556 to 574 residues) binding to PHD2 (181 to 426 residues) (unknown origin) by fluorescence polarization assay
AID1917461	Cytotoxicity against human Hep3B cells assessed as cell viability at 100 ug/ml measured by MTT assay	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues.
AID1901050	Inhibition of PHD2 (unknown origin) at 1 uM measured by fluorescence polarization assay relative to control	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1675362	Selectivity index, ratio of IC50 for PHD1 (unknown origin) by O-phenyl enediamine(OPD) based fluorescence assay to IC50 for PHD2 (unknown origin) by O-phenyl enediamine(OPD) based fluorescence assay
AID1497717	Selectivity ratio of IC50 for JMJD2A (unknown origin) by Alphascreen assay to IC50 for HIF-PHD2 (181 to 426 residues) (unknown origin) by fluorescence polarization assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1543455	Inhibition of recombinant human OGFOD1 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by MALDI-TOF MS analysis	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Inhibition of a viral prolyl hydroxylase.
AID1901068	Antiproliferative activity against human HK-2 cells assessed as decrease in cell viability at 50 uM measured in presence of 10 uM cisplatin after 24 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1497723	Inhibition of HIF-PHD2 (unknown origin) expressed in HEK293 cells harboring HRE-driven luciferase gene assessed as HIFalpha stabilization at 150 uM after 24 hrs by luciferase reporter gene assay relative to control	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497708	Selectivity ratio of IC50 for JMJD3 (unknown origin) by Alphascreen assay to IC50 for HIF-PHD2 (181 to 426 residues) (unknown origin) by fluorescence polarization assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1910212	Agonist activity at human TR beta LBD (202 to 461 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as induction of N-terminal biotinylated coactivator SRC2-3 peptide recruitment by alphascreen assay	2022	Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10	Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID1067648	Antianemic activity in nondialysis chronic kidney disease patient assessed as increase in hemoglobin level at 60 to 150 mg administered twice/thrice weekly for 16 to 24 weeks	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.
AID1901071	Nephroprotective activity against cisplatin-induced acute kidney injury in male C57BL/6 mouse assessed as serum EPO level at 10 mg/kg/day, ip	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1917455	Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO production measured after 24 hrs by ELISA	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues.
AID1497718	Cytotoxicity against human L02 cells assessed as reduction in cell viability at 10 to 100 uM after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1543452	Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-incubated for 5 mins before 2OG as substrate and Fe2 as co-factor addition in presence of L-ascorbate and me	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Inhibition of a viral prolyl hydroxylase.
AID1917752	Induction of HIF-2alpha stabilization in human Hep3B cells assessed as HIF-1alpha level at 1 to 100 uM incubated for 24 hrs by immunoblot analysis	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Improving lipophilicity of 5-(1-acetyl-5-phenylpyrazolidin-3-ylidene)-1,3-dimethylbarbituric acid increases its efficacy to activate hypoxia-inducible factors.
AID1675357	Selectivity index, ratio of IC50 for human ERG expressed in HEK293 cells by PatchLiner assay to IC50 for PHD2 (unknown origin) by O-phenyl enediamine(OPD) based fluorescence assay
AID1497732	Effective permeability of the compound at pH 7.4 by PAMPA	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497728	Inhibition of HIF-PHD2 in human Hep3B cells assessed as upregulation of EPO mRNA level at 50 uM after 10 hrs by RT-PCR method	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1675355	Inhibition of PHD2 in human Hep3B cells assessed as upregulation of HIF-2alpha level after 10 hrs by Western blot analysis
AID1497719	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability at 10 to 100 uM after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497713	Inhibition of HIF-PHD3 (unknown origin) using HIF1-alpha (556 to 574 residues) as substrate in presence of 2-OG preincubated for 30 mins followed by OPD addition measured after 10 mins by fluorescence assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497715	Selectivity ratio of IC50 for HIF-PHD3 (unknown origin) by OPD fluorescence assay to IC50 for HIF-PHD2 (181 to 426 residues) (unknown origin) by OPD fluorescence assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1675360	Selectivity index, ratio of IC50 for KDM3A (unknown origin) in presence of peptide substrate incubated for 30 mins by alpha screen assay to IC50 for PHD2 (unknown origin) by O-phenyl enediamine(OPD) based fluorescence assay
AID1917457	Inhibition of PHD2 in human Hep3B cells assessed as stabilization of HIF-2alpha at 100 uM incubated for 4 hrs	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues.
AID1576662	Inhibition of PHD2 (181 to 426 residues) (unknown origin) using FITC-HIF1alpha (556 to 574 residues) as substrate after 60 mins by fluorescence polarization assay	2019	Journal of medicinal chemistry, 08-22, Volume: 62, Issue:16	Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light.
AID1067649	Antianemic activity in end stage renal disease patient receiving hemodialysis assessed as increase in hemoglobin level at 1.5 to 2 mg/kg, po administered thrice weekly for 6 weeks relative to control	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.
AID1067646	Antianemic activity in human assessed as change in hemoglobin level administered thrice weekly for 12 weeks	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.
AID1497730	Lipophilicity, log D of the compound at pH 7.4 by potentiometric titration method	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1917458	Inhibition of PHD2 in human Hep3B cells assessed as stabilization of HIF-1alpha at 100 uM incubated for 4 hrs	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues.
AID1654632	Substrate activity at aldehyde oxidase in human liver cytosol at 10 uM measured after 3 hrs by UPLC/Q-TOF MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Revisiting Aldehyde Oxidase Mediated Metabolism in Drug-like Molecules: An Improved Computational Model.
AID1884425	Inhibition of PHD2 (181 to 426 residue) (unknown origin) measured by fluorescence polarization assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
AID1675358	Selectivity index, ratio of IC50 for KDM6B (unknown origin) in presence of peptide substrate incubated for 30 mins by alpha screen assay to IC50 for PHD2 (unknown origin) by O-phenyl enediamine(OPD) based fluorescence assay
AID1497729	Dissociation constant, pKa of the compound by potentiometric titration method	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1917460	Inhibition of PHD2 (unknown origin) at 66.7 uM relative to control	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues.
AID1354532	Half life in human at 1 to 2 mg/kg, po administered as two or three times weekly	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
AID1497722	Inhibition of HIF-PHD2 (unknown origin) expressed in HEK293 cells harboring HRE-driven luciferase gene assessed as HIFalpha stabilization at 50 uM after 24 hrs by luciferase reporter gene assay relative to control	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497716	Selectivity ratio of IC50 for JMJD1A (unknown origin) by Alphascreen assay to IC50 for HIF-PHD2 (181 to 426 residues) (unknown origin) by fluorescence polarization assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID734755	Inhibition of human hexahistidine-tagged full-length FTO expressed in Escherichia coli BL21 (DE3) using 3-methylthymidine as substrate assessed as inhibition of 3-methylthymidine conversion to thymidine after 1 hr by liquid chromatographic analysis	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Structural basis for inhibition of the fat mass and obesity associated protein (FTO).
AID1917751	Induction of HIF-1alpha stabilization in human Hep3B cells assessed as HIF-1alpha level at 1 to 100 uM incubated for 24 hrs by immunoblot analysis	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Improving lipophilicity of 5-(1-acetyl-5-phenylpyrazolidin-3-ylidene)-1,3-dimethylbarbituric acid increases its efficacy to activate hypoxia-inducible factors.
AID1354531	Antianemic activity in human assessed as increase in hemoglobin level	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
AID1543454	Inhibition of recombinant human FIH using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by LC-MS analysis	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Inhibition of a viral prolyl hydroxylase.
AID1901053	Inhibition of PHD2 (unknown origin) measured by fluorescence polarization assay	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1675262	Antianemic activity in cisplatin-induced C57BL/6 mouse anemia model assessed as improvement in anemia at 10 mg/kg, po administered every other day for 1 month
AID1675350	Inhibition of PHD2 in human MCF7 cells assessed as stabilization of HIFalpha at 5 to 50 uM incubated for 24 hrs by firefly/renilla luciferase reporter gene assay
AID1901069	Nephroprotective activity against cisplatin-induced acute kidney injury in male C57BL/6 mouse assessed as plasma BUN concentration at 10 mg/kg/day, ip	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1917462	Cytotoxicity against human Hep3B cells assessed as cell viability at 12.5 ug/ml measured by MTT assay	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues.
AID1675356	Inhibition of PHD2 in human Hep3B cells assessed as upregulation of HIF-1alpha level after 10 hrs by Western blot analysis
AID1497721	Cytotoxicity against HUVEC assessed as reduction in cell viability at 10 to 100 uM after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1901066	Antiproliferative activity against human HK-2 cells assessed as decrease in cell viability at 100 uM measured after 24 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1497714	Selectivity ratio of IC50 for HIF-PHD1 (unknown origin) by OPD fluorescence assay to IC50 for HIF-PHD2 (181 to 426 residues) (unknown origin) by OPD fluorescence assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1675343	In vivo inhibition of PHD2 in C57BL/6 mouse assessed as upregulation of EPO plasma level by measuring EPO level at 15 mg/kg, po measured after 4 hrs by ELISA
AID1675361	Selectivity index, ratio of IC50 for PHD3 (unknown origin) to IC50 for PHD2 (unknown origin) by O-phenyl enediamine(OPD) based fluorescence assay
AID1901049	Inhibition of PHD2 (unknown origin) at 0.5 uM measured by fluorescence polarization assay relative to control	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1067650	Antianemic activity in chronic kidney disease patient assessed as hemoglobin level administered for 4 weeks	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.
AID1910213	Binding affinity to human TR beta LBD (202 to 461 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 10 uM in presence of ZnSO4 by thermal shift assay	2022	Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10	Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID1497753	Antianemic activity in C57BL/6 mouse cisplatin-induced anemia model assessed as increase in hemoglobin level at 10 mg/kg, po administered every other day for 30 days relative to control	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497752	Antianemic activity in C57BL/6 mouse cisplatin-induced anemia model assessed as increase in hemoglobin level administered po every other day for 30 days	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497754	Antianemic activity in C57BL/6 mouse cisplatin-induced anemia model assessed as increase in hemoglobin level at 25 mg/kg, po administered every other day for 30 days relative to control	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1901051	Inhibition of PHD2 (unknown origin) at 10 uM measured by fluorescence polarization assay relative to control	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1497709	Inhibition of HIF-PHD2 (181 to 426 residues) (unknown origin) using FITC-HIF1-alpha (556 to 574 residues) as substrate after 60 mins by fluorescence polarization assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1543453	Inhibition of recombinant human PHD2 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by LC-MS analysis	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Inhibition of a viral prolyl hydroxylase.
AID1675261	Antianemic activity in cisplatin-induced C57BL/6 mouse anemia model assessed as improvement in anemia at 25 mg/kg, po administered every other day for 1 month
AID1735098	Inhibition of HIF-PHD2 (unknown origin)	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.
AID1497720	Cytotoxicity against HEK293 cells assessed as reduction in cell viability at 10 to 100 uM after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497751	Upregulation of plasma EPO level in C57BL/6 mouse at 10 to 50 mg/kg, po after 4 hrs by ELISA	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1675359	Selectivity index, ratio of IC50 for KDM4A (unknown origin) in presence of peptide substrate incubated for 30 mins by alpha screen assay to IC50 for PHD2 (unknown origin) by O-phenyl enediamine(OPD) based fluorescence assay
AID1280627	Displacement of FITC-HIF-1alpha (556 to 574 residues) from PHD2 (181 to 426 residues) (unknown origin) after 60 mins by fluorescence polarization assay	2015	ACS medicinal chemistry letters, Dec-10, Volume: 6, Issue:12	Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors.
AID1497712	Inhibition of HIF-PHD2 (181 to 426 residues) (unknown origin) using HIF1-alpha (556 to 574 residues) as substrate in presence of 2-OG preincubated for 30 mins followed by OPD addition measured after 10 mins by fluorescence assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1497748	Upregulation of plasma EPO level in C57BL/6 mouse at 10 mg/kg, iv after 4 hrs by ELISA	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1910211	Agonist activity at wild type human TR alpha LBD expressed in Escherichia coli BL21 (DE3) assessed as induction of N-terminal biotinylated coactivator SRC2-3 peptide recruitment by alphascreen assay	2022	Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10	Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID1901070	Nephroprotective activity against cisplatin-induced acute kidney injury in male C57BL/6 mouse assessed as plasma SCr concentration at 10 mg/kg/day, ip	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1497727	Inhibition of HIF-PHD2 in human Hep3B cells assessed as HIF-2alpha protein stabilization at 50 to 250 uM after 10 hrs by Western blot method	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
AID1917456	In vivo inhibition of PHD2 in ICR mouse assessed as increase in serum EPO production at 10 mg/kg, po and measured after 4 hrs by ELISA	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues.
AID1675341	Induction of erythropoiesis in po dosed C57BL/6 mouse assessed as increase in red blood cell count administered thrice for 3 days measured 4 hrs post last dose
AID1354533	In vivo inhibition of PHD in human assessed as induction of EPO level in serum at 1 mg/kg, po administered as twice weekly measured at 4 to 10 hrs post dose	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
AID1675285	Antianemic activity in cisplatin-induced C57BL/6 mouse anemia model assessed as increase in haemoglobin level administered orally every other day for 1 month
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	59 (31.38)	24.3611
2020's	129 (68.62)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	30 (15.79%)	5.53%
Reviews	24 (12.63%)	6.00%
Case Studies	10 (5.26%)	4.05%
Observational	0 (0.00%)	0.25%
Other	126 (66.32%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
protocatechuic acid protocatechuic acid: RN given refers to parent cpd; structure. 3,4-dihydroxybenzoic acid : A dihydroxybenzoic acid in which the hydroxy groups are located at positions 3 and 4.	2.31	1	0	catechols; dihydroxybenzoic acid	antineoplastic agent; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; human xenobiotic metabolite; plant metabolite
adenine [no description available]	2.21	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	2.53	2	0	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
malic acid malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group.	2.08	1	0	2-hydroxydicarboxylic acid; C4-dicarboxylic acid	food acidity regulator; fundamental metabolite
glycine [no description available]	18.31	166	35	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
oxaloacetic acid Oxaloacetic Acid: A dicarboxylic acid ketone that is an important metabolic intermediate of the CITRIC ACID CYCLE. It can be converted to ASPARTIC ACID by ASPARTATE TRANSAMINASE.. oxaloacetic acid : An oxodicarboxylic acid that is succinic acid bearing a single oxo group.	2.21	1	0	C4-dicarboxylic acid; oxo dicarboxylic acid	geroprotector; metabolite
pyruvic acid Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.	2.53	2	0	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
succinic acid Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.	2.21	1	0	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
amodiaquine Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.	2.25	1	0	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	2.25	1	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
whi p154 WHI P154: an anti-leukemic agent; structure in first source	2.25	1	0
whi p97 [no description available]	2.25	1	0	quinazolines
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	3.56	1	1	aromatic ether; benzimidazoles; pyridines; sulfoxide
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.41	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
temozolomide [no description available]	2.41	1	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	2.41	1	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.21	1	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
calcium acetate calcium acetate: a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer. calcium acetate : The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.	3.7	1	1	calcium salt	chelator
acetonitrile acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.	2.31	1	0	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.25	1	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
limestone Calcium Carbonate: Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.. calcium carbonate : A calcium salt with formula CCaO3.	3.7	1	1	calcium salt; carbonate salt; inorganic calcium salt; one-carbon compound	antacid; fertilizer; food colouring; food firming agent
rhein [no description available]	2.08	1	0	dihydroxyanthraquinone
2,4-pyridinedicarboxylic acid lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4.	2.53	2	0	pyridinedicarboxylic acid
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	2.31	1	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
daminozide daminozide: induces tumors	2.21	1	0	straight-chain fatty acid
d-glutamate [no description available]	2.08	1	0	D-alpha-amino acid; glutamic acid	Escherichia coli metabolite; mouse metabolite
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	2.31	1	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
clodronic acid Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.	2.21	1	0	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	3.7	1	1	benzenes; phenyl acetates
transferrin Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.	7.14	4	1
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.53	2	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	2.31	1	0	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	3.8	1	1	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
atorvastatin [no description available]	3.8	1	1	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
d-lactic acid (R)-lactic acid : An optically active form of lactic acid having (R)-configuration.	2.08	1	0	2-hydroxypropanoic acid	Escherichia coli metabolite; human metabolite
dolomite calcium magnesium carbonate: mineral recommended by lay periodicals as a desirable source of calcium & magnesium, but found to be also a source of potentially toxic heavy metals	3.7	1	1
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.21	1	0	D-glucopyranose	epitope; mouse metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	5.65	4	0	1,2,3-triazole
firefly luciferin Firefly Luciferin: A benzothaizole which is oxidized by LUCIFERASES, FIREFLY to cause emission of light (LUMINESCENCE).. Photinus luciferin : A 1,3-thiazolemonocarboxylic acid consisting of 3,5-dihydrothiophene-4-carboxylic acid having a 6-hydroxybenzothiazol-2-yl group at the 2-position.	2.25	1	0	1,3-thiazolemonocarboxylic acid; benzothiazoles; imidothioate	luciferin
methotrexate [no description available]	2.21	1	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
rhodioloside [no description available]	2.21	1	0	glycoside
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	2.31	1	0	amino acid zwitterion; angiotensin II	human metabolite
fibrin Fibrin: A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.	2.21	1	0	peptide
d-2-hydroxyglutarate (R)-2-hydroxyglutaric acid : The (R)-enantiomer of 2-hydroxyglutaric acid.	2.53	2	0	2-hydroxyglutaric acid	algal metabolite
alpha-hydroxyglutarate, (l)-isomer [no description available]	2.53	2	0	2-hydroxyglutaric acid
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.41	1	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.31	1	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
fumaric acid fumaric acid: see also record for ferrous fumarate; use FUMARATES for general fumaric acid esters. fumaric acid : A butenedioic acid in which the C=C double bond has E geometry. It is an intermediate metabolite in the citric acid cycle.	2.53	2	0	butenedioic acid	food acidity regulator; fundamental metabolite; geroprotector
5-carboxy-8-hydroxyquinoline 5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source	2.53	2	0	quinolines
aconitic acid cis-aconitic acid : The cis-isomer of aconitic acid.	2.53	2	0	aconitic acid	fundamental metabolite
oxalylglycine oxalylglycine: structure given in first source. N-oxalylglycine : An amino dicarboxylic acid that is iminodiacetic acid with an oxo substituent. It is used as an inhibitor of alpha-ketoglutarate dependent (EC 1.14.11.*) enzymes.	2.81	3	0	amino dicarboxylic acid; N-acylglycine	EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor
ku 55933 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source	2.25	1	0
antimycin a Antimycin A: An antibiotic substance produced by Streptomyces species. It inhibits mitochondrial respiration and may deplete cellular levels of ATP. Antimycin A1 has been used as a fungicide, insecticide, and miticide. (From Merck Index, 12th ed). antimycin A : A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.	2.13	1	0	amidobenzoic acid
nutlin-3a nutlin 3: an MDM2 antagonist; structure in first source	2.25	1	0	stilbenoid
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	11.61	27	5
mgl-3196 resmetirom: a thyroid hormone receptor-beta agonist	2.41	1	0
oligonucleotides [no description available]	2.25	1	0
pevonedistat pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.	2.25	1	0	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer
sgx 523 [no description available]	2.25	1	0	aryl sulfide; biaryl; pyrazoles; quinolines; triazolopyridazine	c-Met tyrosine kinase inhibitor; nephrotoxic agent
sgi-1027 SGI-1027: inhibits DNA methyltransferase 1; structure in first source	2.25	1	0
baricitinib [no description available]	2.25	1	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
jnj 42041935 [no description available]	3.18	1	0
jnj38877605 [no description available]	2.25	1	0	quinolines
(5-bromo-3-pyridinyl)-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone [no description available]	2.25	1	0	aromatic carboxylic acid; pyridinemonocarboxylic acid
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	5.87	2	2	benzenes; hydroxycoumarin; methyl ketone
antimycin [no description available]	2.13	1	0
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid [no description available]	2.21	1	0	quinolines
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	3.41	1	0
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid [no description available]	2.21	1	0	organonitrogen heterocyclic compound
bay 85-3934 [no description available]	6.43	7	0
imetelstat [no description available]	2.25	1	0
sgc707 [no description available]	2.25	1	0
gsk1278863 GSK1278863: a HIF prolyl hydroxylase inhibitor. daprodustat : A member of the class of barbiturates that is barbituric acid substituted by cyclohexyl groups at positions 1 and 3, and by a (carboxymethyl)aminocarbonyl group at position 5. It is an inhibitor of hypoxia-inducible factor prolyl hydroxylase developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease.	7.02	8	0
epoetin alfa Epoetin Alfa: A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.	12.27	5	4

Condition	Indicated	Relationship Strength	Studies	Trials
Anoxemia [description not available]	0	6.47	13	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	6.47	13	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	1	20.37	109	38
Chronic Kidney Diseases [description not available]	0	17.59	92	31
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	1	19.59	92	31
Genetic Diseases [description not available]	0	3.09	1	0
Benign Neoplasms [description not available]	0	3.09	1	0
Bowel Diseases, Inflammatory [description not available]	0	3.09	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	3.09	1	0
Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.	0	3.09	1	0
Genetic Diseases, Inborn Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero.	0	3.09	1	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	6	13	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Acute Kidney Failure [description not available]	0	3.21	4	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	0	3.21	4	0
Generalized Resistance to Thyroid Hormone [description not available]	0	2.41	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1	5.07	3	0
Aplasia Pure Red Cell [description not available]	0	3.23	4	0
Red-Cell Aplasia, Pure Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production.	0	3.23	4	0
Chronic Kidney Failure [description not available]	0	7.07	7	4
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	0	7.07	7	4
Liver Steatosis [description not available]	0	2.31	1	0
Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.	0	2.31	1	0
Injury, Ischemia-Reperfusion [description not available]	0	3.04	3	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	0	2.72	2	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	3.04	3	0
Dysmyelopoietic Syndromes [description not available]	0	9.18	7	4
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	1	11.18	7	4
Malnourishment [description not available]	0	3.8	1	1
Innate Inflammatory Response [description not available]	0	4.94	2	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	4.94	2	1
Malnutrition An imbalanced nutritional status resulting from insufficient intake of nutrients to meet normal physiological requirement.	0	3.8	1	1
Injuries, Radiation [description not available]	0	3.2	4	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	0	3.8	1	1
Age-Related Osteoporosis [description not available]	0	2.41	1	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	0	2.41	1	0
Cerebral Infarction, Middle Cerebral Artery [description not available]	0	2.41	1	0
Apoplexy [description not available]	0	2.41	1	0
Acute Ischemic Stroke [description not available]	0	2.41	1	0
Cerebral Ischemia [description not available]	0	2.41	1	0
Ischemic Stroke Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.	0	2.41	1	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	0	2.41	1	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	0	2.41	1	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	2.41	1	0
Chronic Illness [description not available]	0	4.99	2	1
2019 Novel Coronavirus Disease [description not available]	0	2.76	2	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	4.99	2	1
Cirrhosis [description not available]	0	3.01	3	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	0	3.01	3	0
Astrocytoma, Grade IV [description not available]	0	2.41	1	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	0	2.41	1	0
Blood Poisoning [description not available]	0	2.76	2	0
Cardiac Diseases [description not available]	0	2.6	1	0
Endotoxin Shock [description not available]	0	2.6	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	2.6	1	0
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	0	2.6	1	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	0	2.76	2	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	0	2.21	1	0
Atherogenesis [description not available]	0	2.21	1	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	0	2.21	1	0
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	0	2.25	1	0
Ureteral Obstruction Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.	0	7.25	1	0
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	0	2.25	1	0
Cardiovascular Stroke [description not available]	0	3.17	1	0
Injury, Myocardial Reperfusion [description not available]	0	3.57	2	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	3.17	1	0
Bruise [description not available]	0	4.55	1	1
Nasopharyngitis Inflammation of the NASOPHARYNX, usually including its mucosa, related lymphoid structure, and glands.	0	4.55	1	1
Hemorrhage, Retinal [description not available]	0	4.55	1	1
Emesis [description not available]	0	4.55	1	1
Contusions Injuries resulting in hemorrhage, usually manifested in the skin.	0	4.55	1	1
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	4.55	1	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	4.55	1	1
Lung Injury, Acute [description not available]	0	2.25	1	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	0	7.25	1	0
Refractory Anemia [description not available]	0	2.25	1	0
Anemia, Refractory A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy.	0	2.25	1	0
Femur Neck Fractures [description not available]	0	2.31	1	0
Femoral Neck Fractures Fractures of the short, constricted portion of the thigh bone between the femur head and the trochanters. It excludes intertrochanteric fractures which are HIP FRACTURES.	0	2.31	1	0
Rhabdomyolysis Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.	0	2.31	1	0
Anemia, Cooley's [description not available]	0	3.23	1	0
beta-Thalassemia A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.	0	3.23	1	0
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	0	2.31	1	0
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	0	2.31	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	2.31	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	0	2.31	1	0
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	0	2.31	1	0
Hyperoxia An abnormal increase in the amount of oxygen in the tissues and organs.	0	2.31	1	0
Chronic Lung Injury [description not available]	0	2.31	1	0
Hematochezia The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.	0	2.31	1	0
Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.	0	2.31	1	0
Blood Clot [description not available]	0	2.31	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	0	2.31	1	0
Pulmonary Arterial Remodeling [description not available]	0	2.31	1	0
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	0	2.31	1	0
Blood Pressure, High [description not available]	0	7.83	5	4
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	0	2.31	1	0
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	0	2.31	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	7.83	5	4
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	0	2.31	1	0
Encephalopathy, Toxic [description not available]	0	2.31	1	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	2.17	1	0
Corneal Endothelial Cell Damage [description not available]	0	2.17	1	0
Nephritis Inflammation of any part of the KIDNEY.	0	2.17	1	0
Anemias, Iron-Deficiency [description not available]	0	2.15	1	0
Anemia, Iron-Deficiency Anemia characterized by decreased or absent iron stores, low serum iron concentration, low transferrin saturation, and low hemoglobin concentration or hematocrit value. The erythrocytes are hypochromic and microcytic and the iron binding capacity is increased.	0	2.15	1	0
Pulmonary Hypertension [description not available]	0	2.21	1	0
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	0	2.21	1	0
Alloxan Diabetes [description not available]	0	2.21	1	0
Angiogenesis, Pathologic [description not available]	0	2.21	1	0
Cancer of Pancreas [description not available]	0	2.21	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	2.21	1	0
Interstitial Nephritis [description not available]	0	2.21	1	0
Nephritis, Interstitial Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.	0	2.21	1	0
Metabolic Acidosis [description not available]	0	9.82	9	9
Hyperpotassemia [description not available]	0	10.86	13	13
Acidosis A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.	0	9.82	9	9
Hyperkalemia Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)	0	10.86	13	13
Retrolental Fibroplasia [description not available]	0	2.57	2	0
Retinopathy of Prematurity A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)	0	2.57	2	0
Diabetic Glomerulosclerosis [description not available]	0	2.21	1	0
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	0	2.21	1	0
Injuries, Spinal Cord [description not available]	0	2.13	1	0
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	0	2.13	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.13	1	0
Encephalomyelitis, Subacute Necrotizing [description not available]	0	2.13	1	0
Leigh Disease A group of metabolic disorders primarily of infancy characterized by the subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, dysphagia, and lactic acidosis. Pathological features include spongy degeneration of the neuropile of the basal ganglia, thalamus, brain stem, and spinal cord. Patterns of inheritance include X-linked recessive, autosomal recessive, and mitochondrial. Leigh disease has been associated with mutations in genes for the PYRUVATE DEHYDROGENASE COMPLEX; CYTOCHROME-C OXIDASE; ATP synthase subunit 6; and subunits of mitochondrial complex I. (From Menkes, Textbook of Child Neurology, 5th ed, p850).	0	2.13	1	0
Injuries, Tendon [description not available]	0	2.13	1	0
Retinal Pigment Epithelial Detachment [description not available]	0	2.13	1	0
Retinal Detachment Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).	0	2.13	1	0
Cirrhosis, Liver [description not available]	0	2.13	1	0
Liver Dysfunction [description not available]	0	2.13	1	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	0	2.13	1	0
Liver Diseases Pathological processes of the LIVER.	0	2.13	1	0
Vascular Calcification Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.	0	2.13	1	0

fg-4592

Description

Cross-References

Synonyms (67)

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (3)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (67)

Molecular Functions (39)

Ceullar Components (14)

Bioassays (123)

Research

Studies (188)

Study Types

fg-4592

Description

Related Flora

Cross-References

Synonyms (67)

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (3)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (67)

Molecular Functions (39)

Ceullar Components (14)

Bioassays (123)

Research

Studies (188)

Study Types

Related Drugs (74)

Related Conditions (136)